

Sheet 1 of 1FORM PTO-1449, U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:
OC01628KAPPLICATION NO.:
10/664,338APPLICANT:
Michael P. Dwyer et alCONF. NO.: **4130**FILING DATE:
09/17/2003GROUP:
1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<i>SA</i>	AA	US 2004/0018192	01/29/2004	Wakabayashi et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
<i>SA</i>	AL	EP 0 673 937	09/27/1995	Europe				
<i>SA</i>	AM	WO 01/56607	08/09/2001	PCT				
<i>SA</i>	AN	WO 96/34866	11/07/1996	PCT				
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>SA</i>	AQ	Diego Basso et al., "Synthetic Approach to Imidazo[1,2-a]pyridine Derivatives by the Intramolecular Nitrone Cycloaddition Methodology", <i>Tetrahedron</i> , 58, 4445-4450 (2002).
<i>SA</i>	AR	E. Smakula Hand et al., "Teleamination of the Imidazo[1,2-a]pyridine System", <i>J. Org. Chem.</i> , 43(14), 2900-2906 (1978).
	AS	
	AT	
	AU	
	AV	

EXAMINER

E. Hwang

DATE CONSIDERED

9/1/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 1

FORM PTO-1449

DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:
OC01628K

APPLICATION NO.:
10/664,338

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

APPLICANT:
Michael P. Dwyer et al.

(Use several sheets if necessary)

FILING DATE:
09/17/2003

GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
SH	AL WO 02/20523	03/14/2002	PCT			
SH	AM WO 98/37080	08/27/1998	PCT			
SH	AN WO 99/55706	11/04/1999	PCT			
	AO					
	AP					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SH	AQ	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem.</i> (1994), 224 : 771-786.				
	AR	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16 (9): 2986-2999.				
	AS	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243 : 527-536.				
	AT	Bible et al., "Cytotoxic Synergy between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57 : 3375-3380.				
	AU	Shiota et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5- α]pyrimidine", <i>Chem. Pharm. Bull.</i> (1999), 47 (7): 928-938.				
SH	AV	Yasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5- α]pyrimidines.", <i>Chem. Pharm. Bull.</i> (1962), 10 : 620-626				

EXAMINER

Le Hong

DATE CONSIDERED

9/1/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.